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Monday, March 2, 2009 263achannels, whose primary contribution is to the upstroke and plateau of the action
potential; Nav1.5 [INa] (heterologously expressed) and the native cardiac L-type
Ca channel, Cav1.2 [ICaL] (cardiac myocytes). The biophysical properties of
these two cardiac ion channels have been extensively characterized and each
ion channel assay has been pharmacologically validated with reference com-
pounds. In conclusion, this approach is part of our continuing effort to move
to a cellular based in vitro safety approach to provide mechanistic SAR for solv-
ing cardiac safety issues. To date, our ion channel toolbox includes: hERG,
Kir2.1, KvLQT1/minK, Nav1.5 and the native cardiac L-type Ca channel
(Cav1.2); to be used on an as needed basis for cardiac safety evaluation.
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HERG (human ether a go-go related gene) encodes a cardiac potassium channel
that has been linked to delayed repolarization. Due to the large vestibule of the
hERG channel pore, many structurally dissimilar compounds are able to block
the hERG channel. This, along with specific requirement of hERG data by reg-
ulatory authorities, has added to the difficulty of drug discovery. Recently, we
have discovered a series of compounds (hACTs) that do not block hERG, but
actually enhance hERG current. hACT-1({4-[4-(5-trifluoromethyl-1H-pyrazol-
3-yl)-phenyl]-cyclohexyl}-acetic acid) enhanced hERG current by 50 % at
60 mM. In addition, hACT-1 caused concentration-dependent shortening of
the action potential duration in canine Purkinje fibers and guinea pig atrial tissue.
Preliminary studies suggest that binding of hACT-1 (60 mM) does not overlap
sites of typical hERG blockers. hACT-1 did not displace radio labeled dofeti-
lide. Also, in whole-cell voltage clamp studies, combination of hACT-1 with
known hERG blockers (i.e., sotalol and terfenadine) suggest that the com-
pounds are not competing for the same binding site. When applied simulta-
neously with a hERG blocker, the onset of hERG enhancement with hACT-1
occurs prior to block with either sotalol or terfenadine. Block with sotalol
(150 mM) occurs at the same magnitude when used alone (42 %), or in combi-
nation with hACT-1 (44 %). Similarly, the enhancement of hERG current by
hACT-1 is independent of sotalol block, just as the block of hERG current
by sotalol is independent of hACT-1 current enhancement. These effects dem-
onstrate that the binding site for enhanced hERG current is different than the
binding site for block.
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Background: Mutations of SCN5A, gene encoding a-subunit of cardiac
sodium channel, can cause mixed phenotypes of Brugada syndrome (BrS)
and cardiac conduction diseases (CCDs).
Methods:We have identified a novel nucleotide change of SCN5A (4178T>G)
which results in a nonsense mutation, L1393X, in a 36 year-old Caucasian male
who presented with intraventricular conduction delays and BrS type ECG
change. To study biophysical characteristics of L1393X-SCN5A, electrophys-
iological and immunostaining studies were performed using mammalian
expression systems.
Results:WhileWT-SCN5A showed significant currents (93.35 10.6 pA/pF; 1
mg plasmid), L1393X (5 mg) did not generate any significant currents in NIH-
3T3 cells. The cells co-transfected with WT (0.5 mg) and L1393X (0.5 mg)
showed approximately 50% current amplitudes compared to the WT (1 mg).
Voltage-dependency of the steady-state activation and inactivation was not
affected by the co-transfection of L1393X. Immunohistochemical stainings
demonstrated that L1393X proteins were expressed in the plasma membranes.
Conclusion: Our study demonstrated that L1393X-SCN5A does not form
functional channel proteins, which might account for the patient’s mixed
phenotypes of BrS and CCDs.
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Michigan, Ann Arbor, MI, USA.Introduction: Synapse associated protein-97 (SAP97) is a scaffolding protein
expressed in cardiac myocytes. Previous studies have suggested that SAP97 in-
teracts with and modifies properties of ion channels. We have investigated the
functional effect of silencing SAP97 on major repolarizing currents in adult rat
ventricular myocytes (ARVMs).Methods: SAP97 was silenced using a shRNA
expressing adenovirus. The standard patch clamp technique was used to inves-
tigate the effects of this silencing on potassium currents in ARVMs. Control
experiments were carried out in ARVMs infected with a GFP expressing ade-
novirus. Results: Western blot analysis showed that SAP97 was silenced in
ARVM after 3 days in culture. In SAP97 silenced ARVMs, IK1 density was
reduced by ~50% when measured at -100 mV (Holding potential (HP) ¼
-50 mV). Average current density was -1.8550.3 pA/pF, n¼12 as compared
to -3.7650.5 pA/pF, n ¼ 6 in control cells. Depolarization-activated (at
þ60 mV, HP ¼ -70 mV) currents in the ARVM were fitted with a two-expo-
nential function for analysis. Amplitude and kinetic analysis of the fits showed
that there was a 30% decrease in the current density of the first component in
SAP97 silenced ARVMs (951.9 pA/pF, n¼5) as compared to control
(13.550.9 pA/pF, n¼4). SAP97 silencing however did not significantly change
the kinetics of the first component. Time constants averaged 68512 msec and
1.150.1 sec in control versus 121524 msec and 1.4750.21 sec in SAP97 si-
lenced cells. Compared to the control cells, there was no change in the current
density of the second component in SAP97 silenced cells. Current amplitude
averaged 3.150.4 pA/pF (n¼5) and 3.750.2 pA/pF (n¼4), respectively for
SAP97 silenced ARVMs and control. These results suggest that the silencing
of SAP97 has differential effects on potassium currents in adult cardiac
myocytes.
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In the heart, fibroblasts represent the major cell type. They contribute to the
production of the extracellular matrix. Cardiac remodelling during pathological
injury is associated with differenciation of fibroblasts into myofibroblasts. The
aim of this study was to characterize at molecular and functional levels a new
K conductance in these cells.
Among K channel transcripts which were screened by high-throughput real-
time PCR, SUR2 and Kir6.1 mRNAs were found to be the most abundant.
Western-blots showed that SUR2 and Kir6.1 protein expression levels in-
creased with culture duration as fibroblasts differenciated into myofibroblasts.
In the inside-out configuration of the patch-clamp technique, SUR2/Kir6.1
K channels were recorded and showed insensitivity to ATP, inhibition by gli-
benclamide and activation by pinacidil and UDP. These properties are similar
to those reported by Yamada et al (1998) for the SUR2/Kir6.1 molecular sig-
nature. In the whole cell configuration, these channels gave rise to a macro-
scopic glibenclamide-sensitive current which was activated by pinacidil and
which amplitude increased with culture duration. This current was also acti-
vated by the endogenous sphingolipid sphingosine-1-phosphate (S1P) at the
nM concentration range. The activation of this current was found to stimulate
cell proliferation and to decrease IL-6 secretion. All these functional effects
occurred for culture duration greater than 5 days.
In conclusion this work shows for the first time the presence of a glibenclamide-
sensitive current which appears during differenciation of fibroblasts into myo-
fibroblasts. This SUR2/Kir6.1 current, which may be activated in pathological
conditions where fibroblasts differentiate into myofibroblasts and where S1P
level increases, may modulate cardiac ventricular function.TRP Channels
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TRPC3 and TRPC6 are nonselective calcium channels and two members of
the canonical transient receptor potential (TRPC) subfamily expressed on
human erythroblasts. Although they are 73% identical in their amino acids
sequence, they respond differently to erythropoietin (Epo) stimulation. Epo
stimulates a significantly greater increase in calcium influx through TRPC3
(23657% increase above baseline) compared to TRPC6 (7455% above base-
line). TRPC6 also inhibits Epo-stimulated calcium influx in cells cotransfected
